University of New Mexico, The Department of Psychology, Albuquerque, USA.
Sci Rep. 2019 Feb 25;9(1):2712. doi: 10.1038/s41598-019-39462-1.
Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis subspecies (C. indica and C. sativa), and major cannabinoid contents (tetrahydrocannabinol, THC; and cannabidiol, CBD), along with real-time ratings of health symptom severity levels, prior-to and immediately following administration, and reported side effects. A fixed effects panel regression approach was used to model the within-user effects of different product characteristics. Patients showed an average symptom improvement of 3.5 (SD = 2.6) on an 11-point scale across the 27 measured symptom categories. Dried flower was the most commonly used product and generally associated with greater symptom relief than other types of products. Across product characteristics, only higher THC levels were independently associated with greater symptom relief and prevalence of positive and negative side effects. In contrast, CBD potency levels were generally not associated with significant symptom changes or experienced side effects.
联邦障碍和后勤挑战阻碍了对数以百万计的患者体内使用的医用大麻产品实时效果的测量。在 2016 年 6 月 6 日至 2018 年 3 月 5 日期间，3341 人使用移动设备软件 ReleafApp 完成了 19910 次自我管理的大麻疗程，记录内容包括：大麻产品类型（干全天然大麻花、浓缩物、可食用、酊剂、外用药）、燃烧方法（大麻卷烟、大麻烟斗、大麻汽化器）、大麻亚种（印度大麻和大麻亚种）以及主要大麻素含量（四氢大麻酚，THC；和大麻二酚，CBD），以及在给药前后实时报告健康症状严重程度和副作用。采用固定效应面板回归方法对不同产品特性的用户内效应进行建模。在 27 个测量的症状类别中，患者的平均症状改善程度为 3.5（SD=2.6），评分范围为 11 分。干花是最常用的产品，通常与其他类型的产品相比，能带来更大的症状缓解。在产品特性方面，只有较高的 THC 水平与更大的症状缓解和积极与消极副作用的发生呈独立相关。相比之下，CBD 效价水平通常与显著的症状变化或经历的副作用无关。
